3-MeO-PCE (3-Methoxyeticyclidine) is a dissociative compound primarily utilized in scientific studies focused on neuropharmacology, psychotropic modeling, and receptor activity mapping. It serves as a functional analog to PCP and ketamine, offering researchers a compound with distinct pharmacokinetics and a longer action window. It is not intended for human consumption and must only be used in properly equipped research environments.

• NMDA Receptor Antagonism Studies: 3-MeO-PCE binds noncompetitively to NMDA receptors, helping researchers study neural inhibition, memory disruption, and dissociative states.

• Dopaminergic and Sigma-1 Pathway Exploration: The compound displays secondary activity at dopamine transporters and sigma-1 receptors, relevant in studies on emotion, cognition, and motivation.

• Modeling Dissociation and Psychosis: Its unique effects allow laboratories to simulate states resembling schizophrenia or severe depersonalization for neurobehavioral experiments.

• Functional Comparison to Ketamine and PCP: Researchers often use it to draw comparisons between first-generation dissociatives (like PCP) and second-generation analogs (like ketamine).

• Cognitive and Behavioral Testing: It has been applied in controlled rodent models to study working memory, spatial recognition, and motor disruption under dissociative conditions.

• Consciousness and Perception Studies: Due to its profound effects on sensory processing, 3-MeO-PCE is a useful tool in psychopharmacology research focusing on altered states.

• Pharmacokinetic Profiling: Labs also investigate its absorption rate, half-life, and metabolic breakdown, contributing to foundational drug metabolism knowledge.

The legal status of 3-MeO-PCE is determined by the jurisdiction in which it is being purchased, stored, or researched. In many countries, it is unscheduled and can be legally obtained for scientific or analytical research. However, researchers must exercise caution, as analog laws or chemical bans may indirectly apply.

• Unscheduled in Several Countries: In regions like Canada, certain EU nations, and parts of Asia, 3-MeO-PCE is not explicitly scheduled and can be legally purchased for lab research.

• Subject to Analog Laws: In the United States and other nations with analog acts, 3-MeO-PCE may be treated as a controlled substance if intended for human use or deemed similar to a scheduled compound.

• Strictly for Laboratory Use: Even in jurisdictions where it is legal, it is mandated to be used only in research settings—not for personal or recreational use.

• RC Plug Compliance Policy: We do not ship to countries or regions where 3-MeO-PCE is controlled or restricted by local law.

• Import Permit Requirements: Some regions require a license or customs declaration for import of psychoactive or unscheduled chemicals.

• Always Verify Local Laws: Buyers are responsible for understanding and complying with national and local legislation before placing an order.

• Legal Shifts Are Frequent: Research chemicals often undergo regulatory changes, so it’s important to stay updated on policy revisions.

Storing 3-MeO-PCE properly ensures chemical integrity, extends shelf life, and prevents contamination. Due to its molecular sensitivity to light, air, and moisture, maintaining an optimal environment is essential for any laboratory handling this compound.

• Cool Temperature Required: Ideal storage is between 2°C to 8°C in a temperature-stable laboratory refrigerator or cold room to prevent degradation.

• Vacuum-Sealed or Airtight Containers: Exposure to oxygen can cause oxidative breakdown; vacuum-sealing or airtight vials significantly reduces this risk.

• Moisture Control: Hygroscopic conditions can damage the powder’s structure—use desiccants or moisture-barrier containers when storing bulk quantities.

• Amber or Opaque Containers: Light, particularly UV radiation, degrades aromatic ketones; using light-proof containers helps maintain stability.

• Avoid Frequent Openings: Opening the container repeatedly increases air and moisture exposure, so aliquoting small research quantities is advised.

• Labeling and Documentation: Include batch numbers, COA reference, storage start date, and safety data sheet (SDS) reference on all containers for traceability.

• Shelf Life Tracking: Under ideal conditions, 3-MeO-PCE can retain >95% potency for 12–24 months. Beyond this, re-testing for degradation is recommended.

3-MeO-PCE should only be handled in strictly controlled laboratory conditions and is not meant for in vivo human or recreational testing. Lab usage generally involves in vitro studies or animal modeling under regulated conditions, where precision and dosing control are paramount.

• Microgram to Low Milligram Scale: In most studies, starting amounts range from 0.5 mg to 5 mg, depending on the experiment’s design and test subject.

• Gradual Titration Protocol: Always begin with the minimum active quantity and scale up incrementally based on observation and assay requirements.

• Milligram-Precision Scales: Analytical balances with sensitivity down to 0.1 mg are essential to prevent overdose or contamination.

• Dissolution in Solvents: 3-MeO-PCE is typically dissolved in ethanol or DMSO for use in solution-based assays or when applying to cultured tissues.

• Animal Model Adjustments: Rodent-based studies must factor in body mass and administration route to determine safe and meaningful exposure.

• Personal Protective Equipment Required: Gloves, goggles, and lab coats should be worn at all times to avoid accidental dermal or mucosal contact.

• Fume Hood Recommended: Dissolving or manipulating the compound should occur under ventilated conditions to avoid inhalation risk.

3-MeO-PCE is a member of the arylcyclohexylamine class, structurally related to PCP and ketamine. Its molecular architecture enables it to act as a dissociative anesthetic via NMDA receptor antagonism. Understanding its structure helps researchers in designing analogs or assessing receptor binding affinities.

• Core Structure: It consists of a cyclohexanone ring bonded to a phenyl ring substituted with a methoxy group, and an ethylamino side chain.

• IUPAC Name: The formal name is 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone.

• Molecular Formula: C₁₅H₂₃NO₂, indicating 15 carbon atoms, 23 hydrogen atoms, one nitrogen, and two oxygen atoms.

• Molecular Weight: 249.35 g/mol, crucial for dosing, molarity calculations, and solubility predictions.

• SMILES Notation: CCNC1(CCCCC1)C2=CC(=CC=C2)OC, commonly used in cheminformatics software and molecular modeling tools.

• Functional Groups: Contains a ketone group (C=O), a methoxy group (-OCH₃), and a secondary amine (ethylamino), contributing to both its lipophilicity and pharmacodynamics.

• Structure-Activity Relevance: Small structural shifts (like moving the methoxy to another phenyl position) significantly impact receptor affinity, making it a valuable compound for SAR (Structure-Activity Relationship) studies.

The effects of 3-MeO-PCE in laboratory studies are known to be moderate to long-lasting, particularly when compared to similar dissociative compounds. The duration is influenced by variables such as administration method, dose, species used in testing, and the biological half-life of the compound. Its prolonged action makes it a suitable candidate for longitudinal studies involving receptor binding and behavioral modulation.

• Typical Duration: In animal and in vitro models, active pharmacodynamic effects can last between 4 to 8 hours depending on the dosing concentration and metabolic rate.

• Onset Timeline: Observable activity usually begins within 30 to 60 minutes of application, which allows time-sensitive measurements of behavioral or receptor changes.

• Peak Phase: The peak effect period generally occurs around the 1.5 to 3-hour mark, allowing researchers to collect dense, high-relevance data.

• Gradual Offset: The substance exhibits a tapering off of activity rather than a sharp decline, which is helpful for monitoring post-acute effects and residual receptor activity.

• Experimental Variance: Duration may vary between species or cell lines—rodents may metabolize the compound faster or slower depending on genetic differences.

• Influence of Solvent and Route: Intravenous or intracerebral routes result in faster peaks and shorter durations, while oral gavage or dermal application (in controlled studies) may extend the timeline.

• Post-Exposure Monitoring: Laboratories often continue to monitor for residual cognitive or locomotor changes up to 12 hours post-dose due to the compound’s lingering effects.

3-MeO-PCE exhibits a unique pharmacological profile, interacting with several key receptor systems in the brain. Its most prominent activity is as an NMDA receptor antagonist, but it also demonstrates weaker but notable activity at other receptor types, contributing to its broad behavioral and neurochemical effects in research.

• NMDA Receptor Antagonism: The primary mode of action involves non-competitive inhibition of NMDA glutamate receptors, leading to disruptions in synaptic transmission and induction of dissociative states.

• Dopamine Reuptake Inhibition: 3-MeO-PCE shows affinity for dopamine transporters (DAT), which may explain its mild stimulating properties observed in some models.

• Sigma-1 Receptor Activity: Secondary binding at sigma-1 receptors has been documented, influencing perception, sensory gating, and possibly antidepressant-like effects in some animal studies.

• Low Affinity for Serotonin Receptors: Unlike serotonergic psychedelics, 3-MeO-PCE has limited to no activity at 5-HT2A receptors, making its profile dissociative rather than hallucinogenic.

• Minimal GABAergic Modulation: It does not meaningfully affect GABA-A or GABA-B receptors, reducing its sedative potential compared to other CNS depressants.

• Cholinergic Impact: Limited evidence suggests it may slightly interact with muscarinic receptors, but these effects are typically negligible in lab models.

• Neuroplasticity Implications: By altering NMDA receptor activity, 3-MeO-PCE indirectly influences calcium ion flow and neural plasticity mechanisms—important for learning and memory research.

Yes, under strict experimental design, 3-MeO-PCE can be used in combination with other compounds for comparative or synergistic studies. However, such approaches require rigorous control, proper titration, and ethical oversight to avoid unpredictable interactions and toxicity. Pairing dissociatives with other modulators allows researchers to explore dynamic receptor relationships and co-modulatory pathways.

• NMDA Antagonist Comparisons: Combining 3-MeO-PCE with compounds like ketamine or MK-801 helps highlight differences in onset, potency, and receptor specificity.

• Stimulant Pairing: When paired with dopaminergic agents, researchers can investigate the balance between dissociative detachment and psychostimulant drive.

• Receptor Competition Models: Co-administration with sigma-1 agonists or dopamine antagonists can reveal how multiple pathways influence behavioral outcomes.

• Toxicity Threshold Studies: Dose-stacking helps define LD50 values, therapeutic windows, and neurotoxicity markers.

• Cross-Tolerance Testing: Chronic or repeated use in models can assess whether tolerance develops to 3-MeO-PCE or if it alters the efficacy of other substances.

• Neuroprotection or Antagonism Assays: Researchers often explore how co-administration of protective agents (e.g., antioxidants) influences cellular responses to NMDA blockade.

• Always Require Ethical Approval: Combining psychoactive substances in animal or cellular models must be approved by institutional review boards or bioethics committees.

3-MeO-PCE, like most arylcyclohexylamines, is stable under appropriate storage conditions, but it is sensitive to environmental factors such as light, humidity, and air. Maintaining the compound’s integrity over time is critical for research reproducibility and data validity.

• Long-Term Stability: When stored properly, 3-MeO-PCE maintains chemical stability and potency for up to 24 months, making it suitable for longitudinal research programs.

• Degradation Triggers: Exposure to UV light, high humidity, or oxygen significantly accelerates chemical breakdown and may produce inactive or even harmful byproducts.

• Vacuum Packaging Advantage: Storing the compound in vacuum-sealed, light-blocking containers reduces the risk of oxidative and photolytic degradation.

• Desiccant Use: Including a desiccant packet in storage containers helps mitigate moisture exposure and extends shelf life.

• Temperature Sensitivity: Stability decreases rapidly if stored at ambient temperatures for prolonged periods—refrigerated or cool dry storage is required.

• pH Sensitivity in Solution: When dissolved, especially in aqueous solvents, the compound may degrade more rapidly if the solution is not pH-buffered.

• Batch Testing Best Practice: Periodic re-analysis using HPLC or GC-MS ensures the compound remains within expected purity and concentration thresholds.

When used strictly within laboratory settings and under proper safety protocols, 3-MeO-PCE is considered safe for trained researchers. Due to its pharmacological activity, however, accidental exposure must be avoided at all costs. Proper storage, handling equipment, and personnel training are essential to ensure researcher safety.

• Use Personal Protective Equipment (PPE): Researchers must wear gloves, safety goggles, and a lab coat at all times while handling the compound.

• Work in a Fume Hood: All manipulations involving powders or solvents should occur inside a chemical fume hood to avoid airborne exposure or accidental inhalation.

• Avoid Skin or Mucosal Contact: The compound may be absorbed through skin or mucous membranes—double gloving is recommended when handling large quantities.

• Prevent Cross-Contamination: Always use dedicated glassware and tools, and clean surfaces thoroughly after work.

• Label Clearly and Secure Storage: Containers should be labeled with hazard symbols and locked in a chemical-safe storage cabinet away from incompatible substances.

• Follow SDS Guidelines: Review the Safety Data Sheet for instructions on emergency procedures, toxicity, and first aid.

• Disposal Regulations: Dispose of unused material and residues as per local hazardous waste protocols—never discard in sinks or general waste.

Though structurally similar, 3-MeO-PCE and 3-MeO-PCP differ significantly in their pharmacological profiles, receptor affinities, behavioral effects, and durations of action. These differences are critical for researchers seeking targeted results, especially in neuropharmacological and behavioral studies. Understanding how each compound interacts with the central nervous system helps define their unique research applications.

• Potency Differences: 3-MeO-PCP is generally considered more potent than 3-MeO-PCE on a per milligram basis, often requiring smaller dosages to achieve comparable effects in animal models.

• Duration of Action: 3-MeO-PCP typically exhibits a longer active period (up to 10 hours or more), whereas 3-MeO-PCE maintains a moderate 4–8 hour range, depending on variables like dosage and administration method.

• Onset of Effects: 3-MeO-PCE often has a slower and more gradual onset, which allows researchers better temporal control in time-sensitive studies compared to the more abrupt onset of 3-MeO-PCP.

• Receptor Binding Profile: Both compounds are NMDA antagonists, but 3-MeO-PCP shows greater affinity at sigma receptors, which may contribute to increased emotional intensity or dysphoria in certain models.

• Behavioral Impact: 3-MeO-PCP is more likely to produce severe cognitive disorientation, mania-like behavior, and motor disruption, while 3-MeO-PCE may induce more functional or manageable alterations.

• Abuse Potential: From a behavioral pharmacology standpoint, 3-MeO-PCP may pose a higher risk of dependency-related mechanisms in self-administration models.

• Experimental Preference: Due to its smoother and more predictable effects, 3-MeO-PCE is often preferred in studies requiring cognitive participation or long-term monitoring.

Yes, like many sensitive research chemicals, 3-MeO-PCE is susceptible to degradation when exposed to improper environmental conditions. Stability and potency are closely linked to how the compound is stored, handled, and packaged. Maintaining strict storage controls is vital for preserving its chemical efficacy over time.

• Photodegradation: Exposure to light, particularly UV radiation, can initiate chemical breakdown, altering its structure and reducing receptor-binding capacity.

• Oxidation Risk: Oxygen exposure can lead to the formation of oxidized byproducts that may be inactive or even introduce confounding variables in research outcomes.

• Moisture Sensitivity: High humidity or contact with moisture can compromise powder form, leading to clumping, hydrolysis, and loss of structural fidelity.

• Packaging Integrity: If vacuum-sealing is broken or the container is not airtight, the compound may begin degrading within days to weeks, depending on conditions.

• Time-Dependent Decline: Even under ideal storage, 3-MeO-PCE may lose a small percentage of potency over 12–24 months, making re-analysis important for long-term projects.

• Temperature Impact: Leaving the compound at room temperature for extended periods, especially in humid or sunlit environments, accelerates degradation.

• Detection of Degradation: Discoloration, texture changes, or new HPLC peaks in chromatography data are signs the compound has started degrading.

3-MeO-PCE’s principal mechanism of action is its non-competitive antagonism of NMDA (N-methyl-D-aspartate) receptors, a critical class of glutamate receptors involved in memory formation, synaptic plasticity, and learning. This antagonism results in dissociative effects and is central to its value in neurochemical and cognitive research.

• Non-Competitive Binding: 3-MeO-PCE binds at a site distinct from the glutamate binding site, blocking the receptor channel and reducing calcium ion flow, which is vital in studying neuronal signal disruption.

• Inhibition of Synaptic Transmission: NMDA antagonism leads to suppression of excitatory neurotransmission, helping researchers model neurological disorders such as schizophrenia or Alzheimer’s disease.

• Neuroprotective Research: At low concentrations, NMDA blockers like 3-MeO-PCE are investigated for their potential to reduce excitotoxicity following traumatic brain injuries or ischemic events.

• Role in Consciousness Studies: NMDA inhibition alters connectivity between brain regions, making it a powerful tool in investigating consciousness, ego dissolution, and default mode network disruption.

• Impact on LTP and LTD: Long-term potentiation (LTP) and long-term depression (LTD), essential for memory and learning, are impaired under NMDA blockade, allowing for behavioral study of memory loss.

• Comparison with Ketamine: While ketamine also blocks NMDA receptors, 3-MeO-PCE provides longer-lasting effects and less sedation, allowing more robust long-term monitoring in rodent models.

• Behavioral Relevance: Antagonism at these receptors often results in locomotor hyperactivity or catalepsy, both measurable in standard rodent behavioral tests.

Due to its pharmacological versatility, 3-MeO-PCE supports a wide range of scientific investigations, particularly in the fields of neuropharmacology, behavioral psychology, and receptor mapping. Its unique balance of dissociative and stimulant-like properties makes it useful in both theoretical and applied research.

• Neurochemical Studies: It aids in studying the effects of NMDA antagonists on neurotransmitter release, synaptic behavior, and brain wave activity.

• Cognitive Behavioral Experiments: Researchers use 3-MeO-PCE in models to observe effects on decision-making, memory, reaction time, and executive functioning.

• Pharmacokinetics and Metabolism: Laboratories explore how the compound is absorbed, distributed, metabolized, and excreted using plasma assays and liver microsome tests.

• Structure-Activity Relationship (SAR): Its close relation to other arylcyclohexylamines makes it ideal for studies focusing on how molecular alterations affect binding and behavioral outcomes.

• Comparative Pharmacology: It helps contrast dissociative drugs in terms of onset, duration, efficacy, and toxicity across different species or systems.

• Receptor Mapping and Imaging: It is useful in PET scan or fMRI-enabled models that visualize the effects of NMDA receptor inhibition in real-time.

• Forensic Toxicology Research: Due to its increasing appearance in illicit markets, it is studied to develop detection methods and toxicological profiles.

While formal pharmacopeial guidelines are lacking due to its research-only status, internal and independent stability studies have offered insight into the long-term behavior of 3-MeO-PCE under controlled storage conditions. These findings are crucial for labs planning extended studies or bulk storage.

• Observed Shelf Life: Most well-preserved samples show little to no degradation for 12 to 24 months when kept at 2–8°C and in vacuum-sealed, light-resistant containers.

• Vendor-Provided Data: Reputable suppliers like RC Plug conduct periodic batch testing using HPLC and mass spectrometry to confirm ongoing purity and identity.

• pH Influence in Solution: When dissolved for assays, degradation can occur more quickly, particularly in unbuffered or highly acidic/basic solvents.

• Effect of Humidity Exposure: Samples exposed to ambient air or humidity show signs of degradation such as clumping or discoloration within weeks.

• Re-testing Recommendations: For research spanning several months, re-verifying compound integrity every 3–6 months using chromatographic methods is advised.

• Storage Format Matters: Powdered form offers better stability than pre-dissolved solutions, which degrade more rapidly.

• Labeling and Batch Logs: Labs tracking usage and integrity should maintain a compound logbook documenting storage conditions, batch number, and purity re-tests.

3-MeO-PCE is usually supplied in powder or crystalline form, optimized for ease of measurement and handling in laboratory environments. The physical characteristics of the compound are consistent with its classification as an arylcyclohexylamine derivative, and these forms are selected specifically for their stability and versatility in various types of research.

• Crystalline Powder Form: Most common in research settings due to its stability, ease of storage, and precision dosing capabilities.

• White to Off-White Appearance: Color consistency indicates high purity and the absence of organic or chemical contaminants.

• Low Hygroscopicity: While not extremely moisture-sensitive, it should still be kept dry to avoid clumping or degradation.

• Micronized Texture: Some suppliers offer micronized versions that allow for easier dissolution in solvents for solution-based assays.

• Vacuum-Sealed Packaging: RC Plug provides the compound in lab-sealed containers to prevent oxidation and contamination.

• Pre-Weighed Units: Many labs prefer purchasing in pre-measured quantities (e.g., 100 mg, 500 mg) for dosing consistency and audit purposes.

• Compatibility with Organic Solvents: Powder form dissolves well in ethanol, DMSO, and acetone, which are commonly used for creating test solutions.